Astrid Børretzen
Position
Guest Researcher
Affiliation
Publications
Academic article
- Liv Cecilie Vestrheim Thomsen; Alfred Honore; Bjørn Tore Gjertsen et al. (2023). A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC.. (external link)
- Lufei Sui; Suming Wang; Debolina Ganguly et al. (2022). PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. (external link)
- Liv Cecilie Vestrheim Thomsen; Alfred Honore; Lars Anders Rokne Reisæter et al. (2023). A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. (external link)
- Astrid Børretzen; Lars Anders Rokne Reisæter; Anders Ringheim et al. (2023). Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer. (external link)
- Astrid Børretzen; Karsten Gravdal; Svein Andreas Haukaas et al. (2019). FOXC2 expression and epithelial–mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. (external link)
- Astrid Børretzen; Karsten Gravdal; Svein Andreas Haukaas et al. (2021). The epithelial–mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. (external link)
- Bjarte Almås; Lars Anders Rokne Reisæter; Carl Erik Nordvik Markhus et al. (2024). A preoperative magnetic resonance imaging can aid in staging and treatment choice for upper tract urothelial carcinoma. (external link)